Company profile for Elektrofi

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance inje...
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
451 D Street Suite 707 Boston, MA 02210
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/halozyme-completes-acquisition-of-elektrofi-expanding-breadth-of-offerings-in-drug-delivery-302618579.html

PR NEWSWIRE
18 Nov 2025
Halozyme buys Elektrofi for up to $900M
Halozyme buys Elektrofi for up to $900M

03 Oct 2025

// FIERCE PHARMA

https://www.fiercepharma.com/pharma/halozyme-buys-subcutaneous-drug-delivery-peer-elektrofi-900m

FIERCE PHARMA
03 Oct 2025

https://www.prnewswire.com/news-releases/elektrofi-announces-oversubscribed-112-25-million-series-c-financing-to-establish-commercial-scale-gmp-manufacturing-capacity--accelerate-clinical-development-across-its-growing-portfolio-of-partnered-programs-302292148.html

PR NEWSWIRE
31 Oct 2024

https://www.globenewswire.com//news-release/2024/01/03/2803190/0/en/Elektrofi-and-Janssen-Biotech-Enter-Worldwide-Collaboration-and-License-Agreement-to-Exclusively-Develop-up-to-Five-Programs-Utilizing-Elektrofi-s-Formulation-Technology.html

GLOBENEWSWIRE
03 Jan 2024

https://www.globenewswire.com//news-release/2023/10/24/2765417/0/en/Elektrofi-and-Lilly-Enter-Multi-Target-Research-Collaboration-and-License-Agreement.html

GLOBENEWSWIRE
24 Oct 2023

https://www.globenewswire.com/news-release/2023/07/17/2705181/0/en/Elektrofi-Appoints-Victoria-Sluzky-as-Chief-Technology-Officer-to-Drive-Innovation-and-Technical-Excellence.html

GLOBENEWSWIRE
17 Jul 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty